INDIA LIVE DESKNIFTY 50:23,140.50(+0.34%)SENSEX:73,895.74(+0.43%)
RDU Global
🇮🇳
Home/Topics/Companies & Institutions/Summit Therapeutics
Back to Newsroom
🏢Organization Dossier

Summit Therapeutics

Curated news coverage, institutional background, regulatory filings, and investigative reporting across RDU Global.

12 Stories Indexed
Last Updated: Just Now
Verified Entity Intelligence
Global Health & Biotech 06 Oct 2026, 08:29 AM IST

AstraZeneca CEO Says Summit Drug Could Anchor Next Wave of Cancer Combinations After $2 Billion Bet

AstraZeneca Chief Executive Pascal Soriot said Summit Therapeutics’ cancer drug could become a foundation for the next generation of combination therapies, underscoring why the Anglo-Swedish drugmaker has committed about $2 billion to the biotech. The comments come as AstraZeneca and Daiichi Sankyo move to test Summit’s ivonescimab alongside Datroway, a sign that large pharmaceutical groups are racing to secure the most promising assets in oncology.

By RDU Global Wire5 min read
Global Economy & Central Banks18 Nov 2026, 08:00 PM IST

Ukraine Allies Push Back on U.S. Criticism of Deep Strikes Inside Russia as Trump, Putin and Xi Summit Looms

Ukraine’s allies are rejecting U.S. criticism of Kyiv’s deep strikes inside Russia, arguing that the attacks remain a military necessity in a war driven by Russian aggression. The dispute is sharpening diplomatic tensions just as global powers prepare for a planned meeting involving Donald Trump, Vladimir Putin and Xi Jinping, where the war, sanctions and broader security alignments are expected to dominate the agenda.

5 min readRead →
National Governance & Policy17 Nov 2026, 02:00 PM IST

PM Modi at ASEAN-India Summit as Quad Leaders Eye First Meeting Since 2024

Prime Minister Narendra Modi is attending the ASEAN-India Summit in a week that could also see a Quad leaders’ meeting after U.S. President Donald Trump arrives, raising the diplomatic stakes in New Delhi’s regional outreach. The gathering comes at a sensitive moment for Indo-Pacific strategy, with India seeking to balance its ASEAN engagement, Quad coordination and broader economic diplomacy.

5 min readRead →
Global Economy & Central Banks16 Nov 2026, 02:00 PM IST

China Confirms Historic Xi-Trump-Putin Summit as Agenda Spans Nuclear Risks, Trade and War

China has confirmed plans for a rare three-way summit involving Xi Jinping, Donald Trump and Vladimir Putin, setting the stage for one of the most consequential diplomatic encounters in years. The agenda is expected to cover nuclear non-proliferation, the Middle East war, trade policy and, potentially, the conflict in Ukraine, underscoring how tightly global security and economic stability are now intertwined.

6 min readRead →
World Politics & Diplomacy15 Nov 2026, 02:00 PM IST

China Stages Pacific Drills as Taiwan Tensions Rise Ahead of Trump-Xi Summit

China has conducted unannounced military drills in the Pacific in what analysts and officials describe as a calibrated show of force aimed at Taiwan and its supporters. The exercises, combined with reports of a large Chinese maritime presence around the island, underscore Beijing’s willingness to apply pressure just as diplomatic attention turns to the upcoming Trump-Xi summit.

6 min readRead →
National Governance & Policy15 Nov 2026, 08:00 AM IST

Modi to Emphasize Strategic Ties at ASEAN Summit as Trade Pact Talks Stall

Prime Minister Narendra Modi is expected to use the ASEAN-India Summit to deepen strategic and bilateral engagement with Southeast Asian partners even as negotiations over the bloc-wide trade pact remain unresolved. With consensus on the review of the goods trade agreement still elusive, New Delhi is increasingly leaning on country-specific economic ties to sustain momentum in the relationship.

5 min readRead →
National Governance & Policy14 Nov 2026, 08:00 PM IST

Modi to Prioritise Strategic Ties at ASEAN-India Summit as Trade Pact Talks Stall

Prime Minister Narendra Modi is expected to use the ASEAN-India Summit to deepen strategic and bilateral engagement with Southeast Asian partners even as negotiations over the bloc-wide trade pact remain unresolved. With consensus on the broader agreement still elusive, New Delhi is increasingly leaning on country-specific trade and investment channels to sustain momentum in economic ties.

5 min readRead →
Startups & Venture CapitalJust now (02:02 PM IST)

Beam Therapeutics Sues Chinese Biotech and VC-Backed Startup Over Alleged IP Theft

Beam Therapeutics has filed suit against a Chinese biotech company and a venture-capital-backed startup, alleging theft of intellectual property tied to its gene-editing technology, according to STAT. The case adds to mounting tensions over biotech innovation, cross-border technology transfer, and the protection of proprietary research in a sector where patents and trade secrets are central to valuation.

6 min readRead →
Global Markets & Equities25 Oct 2026, 08:00 AM IST

Tango Reports 82% Tumor Response in Pancreatic Cancer Trial, Raising the Stakes in a Crowded Race

Tango Therapeutics said its combination therapy produced an 82% tumor response rate in an early-stage trial involving advanced pancreatic cancer, a result that could sharpen investor attention on one of oncology’s most difficult targets. The data add momentum to the company’s strategy, while also inviting scrutiny over durability, patient selection and whether the response can translate into a meaningful late-stage commercial opportunity.

5 min readRead →
Clean Energy & Climate Transition04 Oct 2026, 08:22 AM IST

Poxvirus Study Reveals a Human Gene It Has Kept and Repurposed for Survival

Scientists have identified a poxvirus carrying a stolen human gene and, unusually, showing signs that it has retained and refined the genetic material over time rather than discarding it. The finding offers a rare window into how viruses can borrow from their hosts and adapt those genes for their own biology, with implications for virology, evolutionary research, and the design of future therapeutics.

5 min readRead →
Global Health & BiotechJust now (03:00 PM IST)

Foghorn Cuts 40% of Staff After Lilly Ends Cancer Pact on Data Concerns

Foghorn Therapeutics is laying off about 40% of its workforce after Eli Lilly terminated a cancer drug collaboration that had been a key strategic and financial pillar for the biotech company. The collapse of the partnership, reportedly tied to concerns over data quality, has intensified pressure on Foghorn’s pipeline and sent its shares sharply lower as investors reassess the company’s near-term prospects.

5 min readRead →
Markets, IPOs & Wealth27 Oct 2026, 04:34 PM IST

Tech Is Pushing Healthcare Into a New Investment Cycle

From biosensors and wearables to 3D-printed skin, reconstructed organs and AI-enabled clinical trials, healthcare technology is moving beyond incremental innovation and into a structural shift. The change is reshaping how care is delivered, how drugs are tested and how investors assess the next wave of growth in health-related markets.

4 min readRead →

🏢 About this Entity

Corporations, startups, regulatory bodies, central banks, ministries and judicial courts. All news mentioning this entity is automatically verified and aggregated into this live intelligence dossier.

Co-Occurring Entities

Entities frequently referenced alongside Summit Therapeutics: